NYSE:HIMS
Hims & Hers Health (HIMS)
Financials 
Technical Analysis 
Aug 14, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Hims & Hers Health, trading under the symbol HIMS-N, has shown promising financial performance in its latest quarter, reporting earnings of 0.08 USD per share, which exceeded analyst estimates by a remarkable 100.62%. The company's revenue for the quarter reached 617.82 million USD, slightly falling short of the projected 619.23 million USD. Looking ahead, analysts predict a modest expectation of 0.01 USD in earnings per share for the upcoming quarter, alongside a revenue forecast of 616.50 million USD. Furthermore, the stock has experienced a surge in social media activity, with mentions increasing by 212% in the past 24 hours. However, the stock's volatility has also been highlighted, depicting it as a challenging investment choice, prone to short-term fluctuations.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentHims & Hers Health, Inc. (listed as Hims on the stock exchange) is a telehealth company that offers a range of wellness and healthcare services primarily via online platforms. Known for its direct-to-consumer approach, the company focuses on dermatology, mental health, and primary care, among other sectors. Hims aims to democratize access to healthcare by offering affordable alternatives to traditional healthcare services. Social media mentions are up 160.6% in the past 24h.
Premium contentHIMS has been picking up plenty of steam recently. It's results have continued to come in strong, it is up 225% year-to-date and it is not overly expensive at 34.5x forward earnings. HIMS is a telethealth platform that connects consumers and healthcare professionals. It has a wide product/service offering and growing subscription based model. Revenue growth has been very high (50%+), and it has been becoming increasingly profitable over recent quarters. The balance sheet also has no debt and it has been increasing cash flows nicely. It has a strong business model and fundamentals while growth is expected to continue to be high. We think it looks good and if profitability continue to ramp up the valuation could look more attractive.
Unlock Premium - Try 5i Free
It's a healthcare platform that lets users talk to doctors and buy generic treatments for various sensitive and embarrassing conditions like baldness and weight. Shares soared 30% when it reported Q4 last February, then kept rising. They reported strong growth, profits and guidance. They reported another beat in May, because they were offering more products, namely weight-loss drugs, including GLP-1 injections which are in high demand. But these aren't the patented drugs from Eli Lilly and Novo Nordisk, but copycats (legal) at a much lower price. Shares jumped on this May 20 news. Then in late June a media report stated that HIMS was getting this drug from a supplier that had previously unreported, ties to fraud and bankruptcy, and that users can get these drugs without a prescription, which opens HIMS to litigation risk. Shares fell back to $20, which is an attractive level to enter. He has mixed feelings. The company was good before GLP-1 and good overall.
- «
- ‹
- 1
- ›
- »
Popular Articles
Hims & Hers Health (HIMS) Frequently Asked Questions
What is Hims & Hers Health stock symbol?
Hims & Hers Health is a American stock, trading under the symbol HIMS (previously HIMS-N on Stockchase) on the New York Stock Exchange (HIMS). It is usually referred to as NYSE:HIMS or HIMS
Is Hims & Hers Health a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on HIMS (previously HIMS-N on Stockchase). 1 analyst recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Hims & Hers Health.
Is Hims & Hers Health a good investment or a top pick?
Hims & Hers Health was recommended as a Top Pick by The Weekly Buzzing Stocks by Billy Kawasaki on 2026-03-12. Read the latest stock experts ratings for Hims & Hers Health.
Why is Hims & Hers Health stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Hims & Hers Health.
Is Hims & Hers Health worth watching?
Hims & Hers Health is followed by 32 investors on Stockchase and is a trending stock that is worth watching.
What is Hims & Hers Health stock price?
On 2026-08-14, Hims & Hers Health (HIMS) stock closed at a price of $28.15.
In the last quarter, the company reported 0.08 USD per share, beating the 0.04 USD estimate by 100.62%. Revenue for the same period reached 617.82 M USD, despite the estimate of 619.23 M USD. For the next quarter, analysts expect 0.01 USD in earnings per share and 616.50 M USD in revenue. Social media mentions are up 212% in the past 24h.